-
公开(公告)号:US20230120018A1
公开(公告)日:2023-04-20
申请号:US18058110
申请日:2022-11-22
Applicant: Genentech, Inc.
Abstract: The present disclosure relates to polypeptide degradation, and in particular to techniques for predicting the likelihood that a peptide bond for a given polypeptide molecule is susceptible to a cleavage reaction. Particularly, aspects of the present disclosure are directed to generating a representation of a polypeptide, performing a molecular-dynamics simulation using the representation to obtain a set of polypeptide conformations, determining, for each polypeptide conformation, a spatial characteristic of an amino acid, estimating a nucleophilic attack distance of each polypeptide conformation based on the spatial characteristic, identifying a reactive conformation that is susceptible to a cleavage reaction based on the nucleophilic attack distance of each polypeptide conformation, determining a free energy of the spatial characteristic of the amino acid in the reactive conformation; and predicting a probability of the side chain of the amino acid being trapped in the reactive conformation based on the free energy.
-
公开(公告)号:US11891437B2
公开(公告)日:2024-02-06
申请号:US17392943
申请日:2021-08-03
Applicant: Genentech, Inc.
Inventor: Amin Famili , Germaine Fuh , Patrick Koenig , Chingwei Vivian Lee , Karthikan Rajagopal
CPC classification number: C07K16/22 , A61K9/0014 , A61K9/0019 , A61K9/0048 , A61K9/06 , A61K9/08 , A61K47/61 , C07K2317/24 , C07K2317/31 , C07K2317/55 , C07K2317/56 , C07K2317/76 , C07K2317/92
Abstract: The present invention provides antibody conjugates that include antibodies (e.g., anti-VEGF antibodies) covalently linked to polymers (e.g., hyaluronic acid (HA) polymers), cysteine engineered antibodies, pharmaceutical compositions thereof, and uses thereof, for example for treatment of disorders associated with pathological angiogenesis (e.g., ocular disorders).
-
公开(公告)号:US10906968B2
公开(公告)日:2021-02-02
申请号:US16033353
申请日:2018-07-12
Applicant: Genentech, Inc.
Inventor: Patrick Koenig , Chingwei Vivian Lee , Karthikan Rajagopal , Amin Famili , Germaine Fuh
IPC: C12N15/10 , C12N15/115 , C07K16/22 , A61K47/60 , A61K47/61 , A61K39/395 , A61K47/34 , C07K14/475 , C07K16/44 , C07K16/46 , A61K39/00
Abstract: The present invention provides anti-VEGF antibodies and compositions that include anti-VEGF antibodies (e.g., antibody conjugates, fusion proteins, and polymeric formulations), and uses thereof, for example for treatment of disorders associated with pathological angiogenesis. The present invention also provides methods of identifying antibody variants with improved properties, for example, enhanced binding affinity, stability, pharmacokinetics, and/or expression.
-
公开(公告)号:US10072075B2
公开(公告)日:2018-09-11
申请号:US15274612
申请日:2016-09-23
Applicant: Genentech, Inc.
Inventor: Patrick Koenig , Chingwei Vivian Lee , Karthikan Rajagopal , Amin Famili , Germaine Fuh
IPC: C07K16/22 , A61K39/395 , A61K47/34 , C07K14/475 , C07K16/44 , C07K16/46 , C12N15/10 , C12N15/115 , A61K47/60 , A61K47/61 , A61K39/00
CPC classification number: C07K16/22 , A61K39/3955 , A61K47/34 , A61K47/60 , A61K47/61 , A61K2039/505 , A61K2039/54 , C07K14/475 , C07K16/44 , C07K16/468 , C07K2317/14 , C07K2317/21 , C07K2317/24 , C07K2317/31 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/76 , C07K2317/90 , C07K2317/92 , C07K2317/94 , C07K2318/20 , C07K2319/30 , C07K2319/31 , C12N15/1037 , C12N15/115 , C12N2310/16
Abstract: The present invention provides anti-VEGF antibodies and compositions that include anti-VEGF antibodies (e.g., antibody conjugates, fusion proteins, and polymeric formulations), and uses thereof, for example for treatment of disorders associated with pathological angiogenesis. The present invention also provides methods of identifying antibody variants with improved properties, for example, enhanced binding affinity, stability, pharmacokinetics, and/or expression.
-
公开(公告)号:US12121586B2
公开(公告)日:2024-10-22
申请号:US17129251
申请日:2020-12-21
Applicant: Genentech, Inc.
Inventor: Patrick Koenig , Chingwei Vivian Lee , Karthikan Rajagopal , Amin Famili , Germaine Fuh
IPC: C40B30/04 , A61K39/395 , A61K47/34 , A61K47/60 , A61K47/61 , C07K14/475 , C07K16/22 , C07K16/44 , C07K16/46 , C12N15/10 , C12N15/115 , A61K39/00
CPC classification number: A61K47/61 , A61K39/3955 , A61K47/34 , A61K47/60 , C07K14/475 , C07K16/22 , C07K16/44 , C07K16/468 , C12N15/1037 , C12N15/115 , C40B30/04 , A61K2039/505 , A61K2039/54 , C07K2317/14 , C07K2317/21 , C07K2317/24 , C07K2317/31 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/76 , C07K2317/90 , C07K2317/92 , C07K2317/94 , C07K2318/20 , C07K2319/30 , C07K2319/31 , C12N2310/16
Abstract: The present invention provides anti-VEGF antibodies and compositions that include anti-VEGF antibodies (e.g., antibody conjugates, fusion proteins, and polymeric formulations), and uses thereof, for example for treatment of disorders associated with pathological angiogenesis. The present invention also provides methods of identifying antibody variants with improved properties, for example, enhanced binding affinity, stability, pharmacokinetics, and/or expression.
-
公开(公告)号:US11111291B2
公开(公告)日:2021-09-07
申请号:US16572822
申请日:2019-09-17
Applicant: Genentech, Inc.
Inventor: Amin Famili , Germaine Fuh , Patrick Koenig , Chingwei Vivian Lee , Karthikan Rajagopal
Abstract: The present invention provides antibody conjugates that include antibodies (e.g., anti-VEGF antibodies) covalently linked to polymers (e.g., hyaluronic acid (HA) polymers), cysteine engineered antibodies, pharmaceutical compositions thereof, and uses thereof, for example for treatment of disorders associated with pathological angiogenesis (e.g., ocular disorders).
-
公开(公告)号:US10899828B2
公开(公告)日:2021-01-26
申请号:US16033499
申请日:2018-07-12
Applicant: Genentech, Inc.
Inventor: Patrick Koenig , Chingwei Vivian Lee , Karthikan Rajagopal , Amin Famili , Germaine Fuh
IPC: C07K16/22 , A61K47/61 , A61K39/395 , C07K16/44 , C07K16/46 , A61K39/00 , A61K47/60 , A61K47/34 , C07K14/475 , C12N15/10 , C12N15/115
Abstract: The present invention provides anti-VEGF antibodies and compositions that include anti-VEGF antibodies (e.g., antibody conjugates, fusion proteins, and polymeric formulations), and uses thereof, for example for treatment of disorders associated with pathological angiogenesis. The present invention also provides methods of identifying antibody variants with improved properties, for example, enhanced binding affinity, stability, pharmacokinetics, and/or expression.
-
-
-
-
-
-